QGEN
HealthcareQiagen N.V. · Medical - Diagnostics & Research · $7B
What is Qiagen N.V.?
Qiagen N.V. is a global life sciences company headquartered in Venlo, Netherlands, specializing in molecular diagnostics and sample preparation technologies. Its solutions help researchers and clinicians transform biological samples into actionable molecular insights.
Qiagen generates revenue by selling consumables, instruments, and assays that support nucleic acid purification, PCR-based analysis, and molecular diagnostics. Customers span clinical labs, pharmaceutical research, forensics, and public health organizations. The company's recurring consumables model — where instruments drive ongoing kit purchases — underpins a relatively predictable revenue stream across its global customer base.
Qiagen was founded in 1996 and is headquartered in Venlo, Netherlands.
- Nucleic acid purification kits and sample stabilization consumables
- PCR and digital PCR instruments and reagents
- Molecular diagnostic assays for infectious disease, oncology, and prenatal testing
- Human identification and forensics assay solutions
Is QGEN a Good Stock to Buy?
UQS Score rates QGEN as Good overall, reflecting a balanced profile across its five analytical pillars.
The Risk pillar stands out as the strongest element of Qiagen's profile, suggesting the business carries relatively low financial and operational risk compared to sector peers. Quality and Valuation also register as Good, indicating the company's fundamentals and current pricing are reasonably aligned.
The Moat and Growth pillars both rate Neutral, pointing to a competitive positioning and near-term expansion trajectory that are in line with — but not clearly ahead of — the broader life sciences tools sector.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does QGEN pay dividends?
Yes — Qiagen N.V. pays a dividend.
Qiagen pays a regular dividend, which is relatively uncommon among mid-cap life sciences tools companies. This reflects a degree of financial maturity and cash generation discipline. Income-oriented investors may find the dividend noteworthy, though the primary investment case centers on the company's recurring consumables business rather than yield alone.
When does QGEN report earnings?
Qiagen reports earnings on a quarterly cadence, typical for internationally listed equities traded on US exchanges.
Qiagen's recent results have reflected the broader normalization in molecular diagnostics demand following the pandemic-era surge. The company has focused on sustaining its consumables revenue base and expanding its diagnostic assay portfolio across multiple disease areas.
For the most recent quarter's results and guidance, visit Qiagen's official investor relations page.
QGEN Price History
-9.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Qiagen N.V.?
Based on Qiagen N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
QGEN Long-term Outlook
Qiagen's Neutral Growth pillar suggests the company is navigating a period of steady rather than accelerating expansion. Its Strong Risk profile provides a stable foundation, and the Good Valuation label indicates the stock is not pricing in aggressive growth assumptions. The outlook is shaped by the pace of adoption for its diagnostic platforms and the durability of its consumables-driven revenue model.
Growth drivers
- Expanding adoption of molecular diagnostic assays in clinical and public health settings
- Recurring consumables demand tied to a growing installed instrument base
- Growth in oncology and infectious disease testing applications
Key risks
- Continued normalization of pandemic-related testing demand
- Competitive pressure from larger life sciences tools companies
- Currency and macroeconomic headwinds given Qiagen's global revenue exposure
QGEN vs Peers
Qiagen operates in a competitive life sciences tools and diagnostics landscape alongside several well-capitalized peers.
Charles River focuses primarily on preclinical contract research services, giving it a different revenue model centered on drug development outsourcing rather than consumables and diagnostics.
ICON is a clinical research organization whose business is built around managing clinical trials, placing it further along the drug development pipeline than Qiagen's sample-to-insight tools.
Revvity competes more directly with Qiagen in life sciences instrumentation and diagnostics, with particular strength in newborn screening and applied genomics markets.
Frequently Asked Questions
What does Qiagen do?
Qiagen provides sample preparation and molecular diagnostics solutions that help laboratories extract and analyze genetic material from biological samples. Its products — including purification kits, PCR instruments, and diagnostic assays — serve clinical, research, forensics, and public health customers worldwide.
Does QGEN pay dividends?
Yes, Qiagen pays a regular dividend. This is relatively uncommon for a mid-cap life sciences tools company and reflects the business's financial stability. Investors seeking income alongside exposure to the molecular diagnostics sector may find this relevant to their assessment.
When does QGEN report earnings?
Qiagen reports financial results on a quarterly basis, consistent with standard practice for US-listed equities. For the exact timing of upcoming earnings releases, check Qiagen's investor relations page directly, as our platform does not publish forward earnings dates.
Is QGEN a good stock to buy?
UQS Score rates QGEN as Good overall. The Risk pillar is the standout strength, while Moat and Growth are Neutral. Whether QGEN fits your portfolio depends on your own investment criteria — the full pillar breakdown available to Pro members provides a more detailed view.
Is QGEN overvalued?
The UQS Valuation pillar for QGEN rates as Good, suggesting the stock is not significantly stretched relative to its fundamentals. This does not constitute a price target or recommendation — it reflects a relative assessment within the life sciences tools sector.
How does QGEN compare to its competitors?
Qiagen's closest peers include Revvity in life sciences instrumentation and diagnostics, and Charles River Laboratories and ICON in contract research services. Qiagen differentiates through its consumables-heavy model and broad molecular diagnostics assay portfolio. UQS Pro members can view side-by-side pillar comparisons.
What is QGEN's market cap bracket?
Qiagen is classified as a mid-cap company. This places it in a segment that typically offers more established operations than small-caps while retaining more growth optionality than mega-cap life sciences conglomerates.
Who founded Qiagen?
Qiagen was founded in 1996. Detailed founding history, including the names of its founders, is widely available through the company's official corporate history and public filings.
Is QGEN a long-term quality stock?
As a long-term quality indicator, QGEN's Good overall UQS Score — anchored by a Strong Risk pillar and Good Quality rating — suggests a reasonably durable business. The Neutral Moat and Growth pillars are worth monitoring for investors with a multi-year horizon. Pro members can access the complete analytical view.
What is the main competitive advantage of Qiagen?
Qiagen's primary competitive advantage lies in its integrated sample-to-insight model, where proprietary consumables are paired with its instrument platforms. This creates recurring revenue as customers who adopt Qiagen instruments continue purchasing its kits and reagents over time.
Unlock Full QGEN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for QGEN
- ✓Access detailed financial metrics and trend data
- ✓Compare QGEN side-by-side with Revvity, Charles River, and ICON
- ✓Screen for similar mid-cap healthcare stocks using UQS presets
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
QGEN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 59.4 | 63.6 | 43.0 | 46.4 | 75.6 | 80.8 | -0.8 |
| May 16, 2026 | 60.2 | 64.4 | 43.0 | 46.8 | 76.0 | 83.6 | -0.4 |
| May 4, 2026 | 60.6 | 63.4 | 43.0 | 49.1 | 80.3 | 81.2 | -0.6 |
| May 3, 2026 | 61.2 | 63.4 | 43.0 | 51.5 | 80.3 | 81.8 | +0.5 |
| May 1, 2026 | 60.7 | 63.4 | 43.0 | 51.5 | 80.3 | 78.2 | -0.1 |
| Apr 26, 2026 | 60.8 | 63.4 | 43.0 | 52.2 | 80.3 | 78.4 | +0.3 |
| Apr 19, 2026 | 60.5 | 63.4 | 43.0 | 52.2 | 80.3 | 76.3 | 0.0 |
| Apr 18, 2026 | 60.5 | 63.4 | 43.0 | 52.2 | 80.3 | 76.0 | -0.8 |
| Apr 14, 2026 | 61.3 | 63.4 | 43.0 | 52.2 | 80.3 | 81.5 | -0.2 |
| Apr 12, 2026 | 61.5 | 63.4 | 43.0 | 52.2 | 80.3 | 82.5 | +0.1 |
QGEN — Pillar Breakdown
Quality
— 63.6/100 (25%)Qiagen N.V. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 46.4/100 (20%)Qiagen N.V. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 75.6/100 (15%)Qiagen N.V. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 80.5/100 (15%)Qiagen N.V. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 43/100 (25%)Qiagen N.V. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for QGEN.
Score Composition
Financial Data
More Stock Analysis
How is the QGEN UQS Score Calculated?
The UQS (Unified Quality Score) for Qiagen N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Qiagen N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Qiagen N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.